AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

Inclusion Criteria

• - Participants must be at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place.
• - Eastern Cooperative Oncology group (ECOG) performance status of ≤ 2.
• - Documentation of Multiple Myeloma (MM) as defined by International Myeloma Working Group (IMWG) Diagnostic Criteria for Multiple Myeloma. Site should ensure that Multiple Myeloma diagnosis is confirmed in accordance with the IMWG Diagnostic Criteria.
• - Participants must have one or more of the following measurable disease criteria:
• (a) Serum M-protein level ≥ 0.5 g/dL.
• (b) Urine M-protein level ≥ 200 mg/24h.
• (c) Serum immunoglobulin free light chain ≥ 10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio.
• -Adequate organ and bone marrow function assessment at screening according to the hematological, hepatic, and renal parameters listed in the CSP.
• -Participants must have received at least 3 prior lines of treatment which include a proteasome inhibitor (e.g., bortezomib), an immunomodulator (e.g., lenalidomide), and an anti-CD38 antibody (e.g., daratumumab).
• Principal